Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.

c-erb-B2 expression was successfully generated both in vitro and in vivo, and anti-c-erb-B2 antibody produced highly significant responses with approximately 30–40% complete clinical response against B16, a highly aggressive melanoma tumor cell line.

also in 132,142 other papers